Helping the immune system recognize glioblastoma tumors
Regulation of Tumor Immunogenicity in Glioblastoma
This project looks at ways to make glioblastoma tumors more visible to a patient's immune system so immunotherapy might work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11299535 on NIH RePORTER |
What this research studies
The researchers are studying a protein called PP2A in glioblastoma cells to see how it controls signals that tell the immune system a tumor is present. In lab-grown tumor cells and animal models they lower PP2A activity and observe increased interferon signaling, higher MHC‑I on tumor cells, and more T cells entering tumors. They are studying how cytoplasmic double-stranded DNA and the cGAS‑STING pathway contribute to these immune changes. The goal is to find approaches that could sensitize glioblastoma to checkpoint-blocking immunotherapies used in patients.
Who could benefit from this research
Good fit: Adults (21+) with glioblastoma or those interested in new immune-based treatment approaches for this disease are most relevant to this work.
Not a fit: People with other types of cancer, children under 21, or patients whose tumors have very different biology are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could make immunotherapies effective for some people with glioblastoma, potentially improving tumor control and survival.
How similar studies have performed: Related lab and animal studies—including data showing that inhibiting PP2A can improve anti‑PD‑1 responses in preclinical models—are promising, but immunotherapy has not yet shown consistent success in people with glioblastoma.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Ho, Sze Chun Winson — University of California, San Francisco
- Study coordinator: Ho, Sze Chun Winson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.